Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Primary Myelofibrosis 4Neoplasms 3Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Azacitidine 38Cytarabine 37venetoclax 34fludarabine 28Cyclophosphamide 21Daunorubicin 18fludarabine phosphate 17Decitabine 16Specimen Handling 15Tacrolimus 14Busulfan 13Injections 12Biopsy 12Melphalan 11Granulocyte Colony-Stimulating Factor 11CPX-351 11Mycophenolic Acid 10Idarubicin 10Stem Cell Transplantation 9Whole-Body Irradiation 8Etoposide 8decitabine and cedazuridine drug combination 7Thiotepa 7Mitoxantrone 7enasidenib 6Peripheral Blood Stem Cell Transplantation 6Methotrexate 6ivosidenib 5gilteritinib 5Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myeloid, Acute × navitoclax × Clear all
NCT05222984 2026-04-20

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

City of Hope Medical Center

Phase 1 Active not recruiting
17 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
16 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡